30 closest matches · ranked by relevance
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Infectious Gastroenteritis
Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants
Norovirus Infection
Primary: Frequency of Norovirus Gastroenteritis (NVG) — 5; 4 Participants
Gastroenteritis
Primary: Number of Participants With Modified Vesikari Scale Score >=9 — 55; 60 Participants — p=0.83
Gastroenteritis Norovirus
Primary: The Occurrence of Norovirus-associated Illness in Secretor Positive Participants Through Day 4 After Challenge. — 3; 2; 7; 0 Participants
Healthy Volunteers
Primary: Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding…
Gastroenteritis · Dehydration
Primary: Estimating the Incidence of Rotavirus Gastroenteritis Associated Hospitalization in Children < 5 Years of Age — 428 Participants
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Diarrhea
Primary: Duration of Diarrhea — 2; 2 days — p=0.43
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Norovirus Infections
Primary: Number of Participants With Solicited Symptoms of Reactogenicity (Gastrointestinal [GI] and Systemic) — 20; 20; 2; 9 Participants
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Norovirus Infections
Primary: Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) — 34; 37 Participants
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Prevention From Norovirus Infection
Primary: Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer…
ETEC Diarrhea
Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea
Vibrio Infections
Primary: Number of Participants With Diagnosed Non-cholerae or Non-O1/O139 Vibrio Infection — 20; 7; 2; 18 Participants
Rotavirus Infections · Gastroenteritis · Diarrhea
Primary: Matched VE Participants — 26; 22; 16; 1 participants
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
Gastroenteritis · Gastritis
Primary: Treatment Success From 30 Minutes Through 24 Hours After First Dose of Study Medication - ITT Population — 126; 70; 12; 5 Participants — p=0.0406
Gastrointestinal Diseases
Primary: Device Success Defined as the Ability to Record Myoelectric Signals in Study Subjects. — 88 participants
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Prematurity · Intestinal Permeability
Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932
Infectious Disease
Primary: Confirm Etiologies Among Suspected COVID-19 Cases — 151; 21; 13 Participants
Cryptosporidium Infection, Cryptosporidiosis
Primary: Percentage of Participants With Cryptosporidium Infection From 72 Hours to 10 Days Post ABO809 Oral Administration — 50; 57.1; 60.0 percentage of participants
Rotavirus Infection
Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants
Gastro-oesophageal Reflux
Primary: Number of Refluxes — 0.48; 0.97 number of refluxes
Rotavirus Diarrhea · Vaccine Virus Shedding · Tropical Enteropathy
Primary: Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial) — 99; 109 Participants — p=0.4
Endoscopy, Gastrointestinal
Primary: Qualitative Interview Study — 18; 21 Participants